⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467490 | 1.00 | — | — | |
| SCHEMBL29770800 | 0.81 | — | — | |
| SCHEMBL609820 | 0.81 | — | — | |
| SCHEMBL29408229 | 0.79 | — | — | |
| SCHEMBL4883086 | 0.79 | — | — | |
| SCHEMBL599850 | 0.79 | — | — | |
| SCHEMBL12958842 | 0.75 | — | — | |
| SCHEMBL14611549 | 0.75 | — | — | |
| SCHEMBL13390587 | 0.75 | — | — | |
| SCHEMBL17703514 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117065726-A | Environment-friendly adsorptive material and preparation method thereof | 蚌埠市天星树脂有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| WO-2025137146-A1 | SUBSTITUTED HETEROARYL ANALOGS AND USES THEREOF FOR THE TREATMENT OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | MOUKHA CHAFIQ OMAR (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4514790-A1 | COMPOUNDS FOR INHIBITING KIF18A | Volastra Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-7297708-B2 | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1569917-A4 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-08-15 | — | — | EP | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| EP-1569917-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | Cytopia PTY Ltd (AU) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052868-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2004-06-24 | — | — | WO | disclosed |
| US-20030229091-A1 | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
| WO-2003022820-A1 | HETEROAROMATIC SUBSTITUTED CYCLOPROPANE AS CORTICOTROPIN RELEASING HORMONE | BRISTOL-MYERS SQUIBB PHARMA COMPANY. (US) | 2003-03-20 | — | — | WO | disclosed |